Hepatitis C related kidney disease

Slides:



Advertisements
Similar presentations
Egyptian Guidelines For Management of Chronic Hepatitis B
Advertisements

Hepatitis C Treatment in Corrections: New Medicine, New Challenges
Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.
Epidemic hemorrhagic fever ----hemorrhagic fever with renal syndrome ， HFRS.
Risk of invasive H. influenzae disease in patients with chronic renal failure: a call for vaccination? M. Ulanova, S. Gravelle, N. Hawdon, S. Malik, D.
Common Communicable Diseases
Common Communicable Diseases
Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.
Hepatitis C and You  2014 Greenview Hepatitis C Fund All Rights Reserved.
Hepatitis B.
Liver Disease and Thalassaemia George Constantinou.
Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV versus Interferon alfa-2b RIBAVIC STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.
Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.
Hepatitis web study Hepatitis web study Peginterferon alfa -2a+/- Ribavirin versus Interferon alfa-2b + Ribavirin Phase 3 Treatment Naïve, Chronic HCV.
Vasculitides (Vasculitis) Dr. Raid Jastania. Vasculitis Inflammation of the walls of the vessels Causes of inflammation: –Infectious, physical, chemical,
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision of Prof.
Iva Pitner Mentor: A. Žmegač Horvat
Hep 202 Just when you thought you knew everything.
Hepatitis C Disease & Treatment.
Vasculitis and connective tissue disease – just a taster!! The common and the rare!!
Module 6: Treatment options. Module goal To enable participants understand the best current treatment options, factors that influence outcomes and potential.
Vasculitis Hisham Alkhalidi.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a +/- Ribavirin for Chronic HCV Phase 3 Treatment Naïve, Chronic HCV Fried MW, et. al. N Engl.
Hepatitis B and C: A silent but deadly epidemic Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University Richmond, Virginia.
Greenview Hepatitis C Fund Deborah Green Home: Cell: /31/2008.
 Hepatic Pathology and Respiratory System Topics in Human Pathophysiology Fall 2011 Gilead Drug Safety and Public Health.
Wyoming Department of Health Communicable Diseases
Hepatitis LINK Viral Hepatitis is a group of disease that infect the liver. Three viruses - Hepatitis A, Hepatitis B and Hepatitis C are the most frequent.
This is the most comprehensive compilation of epidemiological information on Hepatitis C Graciously provided by the University Hepatitis Center (last updated.
NICE Guidelines on the Use of Ribavirin and Interferon Alpha for Hepatitis C Matt Johnson and Dr. Hunt / Asante / Jenkins.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Acute Glomerulonephritis. Definition and Incidence Acute Glomerulonephritis (acute nephritic syndrome) is the sudden onset of: – Haematuria (macroscopic/microscopic)
Vasculitis Sufia Husain Pathology Department KSU, Riyadh March 2014.
Nephrology Diseases & Chemotherapy. Idiopathic Nephrotic Syndrome (NS) Caused by renal diseases that increase the permeability across the glomerular filtration.
Hepatitis C: The Next Tsunami Danny Jenkins Cri-Help Common Ground – The Westside HIV Community Center We Write the Grants
HEPATITIS C VIRUS Presented By: Rabia Ejaz Tahira Karim Hafsa Iftikhar.
Hepatitis B - Sexually Transmitted Infection - Infects the liver and causes inflammation - About 1/3 people in the world have Hepatitis B - Can lead to.
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
Vasculitis Vasculitis arises when immune system mistakenly attacks blood vessels. What causes this attack isn't fully known, but it can result from infection.
Hepatitis C+ Recipients: Considerations for Exclusion Emily A. Blumberg, M.D.
By: Megan Agren, Keriann Pfleger, and Crystal Forkey.
Pharmacology of Interferon. Interferon Natural Interferons Man Made Interferons (Recombinant)
Hepatitis. Hepatitis is an inflammation of the liver. Hepatitis is caused by several types of viruses as well as drug and chemical toxicity.
Hepatitis Inflammatory Disease of the Liver. Hepatitis A,B,C,…. What is Hepatitis? Inflammation of the Liver What can cause Hepatitis? * Virus – A, B,
+ By: Sydney Freedman. + General Background 1895: Germany, smallpox outbreak Led to Jaundice Liver doesn’t destroy blood cells properly 1942: United States,
Vasculitis.
Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin in Blacks & Non-Hispanic Whites Phase 3 Treatment Naïve, Chronic HCV Muir AJ,
1 INFLUENZA VIRUS. 2 ‘FLU’ True influenza –influenza virus A or influenza virus B (or influenza virus C infections - much milder) Febrile (showing signs.
Hepatitis C.
Hepatitis is an inflammation of the liver. The condition can be self- limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer WHAT IS.
Hepatitis web study Hepatitis web study Boceprevir with PEG + RBV in Genotype 1 SPRINT-1 Phase 2 Treatment Naïve Kwo PY, et al. Lancet. 2010;376:
Hepatitis B Fahad Alanazi.
Glomerulonephritis By Dr. Abdelaty Shawky Associate professor of pathology.
Chapter 14: Bloodborne Pathogens. Bloodborne pathogens are transmitted through contact with blood or other bodily fluids Hepatitis, especially hepatitis.
Hepatitis C Infection By: S/N Maryam Omar. Introduction  Thalassemia patient require life long blood transfusion to sustain their growth and development.
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B. New Engl J Med 2013;
Pharmacology of Interferon Downloaded from
Viral hepatitis overview Itodo Ewaoche 27/02/2015.
Hepatitis Viral Hepatitis is a group of disease that infect the liver. Three viruses - Hepatitis A, Hepatitis B and Hepatitis C are the most frequent viruses.
What is Hep C Dave Stafford.
Peginterferon alfa-2b Drugbank ID : DB00022
Severe Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by telaprevir.   I. Gallais Sérézal1, M. Delage1, V. Grando-Lemaire2, A. Lévy3,
Hepatitis Viral Hepatitis is a group of disease that infect the liver. Three viruses - Hepatitis A, Hepatitis B and Hepatitis C are the most frequent viruses.
Extrahepatic Manifestations of HCV Infection
Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Presentation transcript:

Hepatitis C related kidney disease Clinical Practice Guidelines – bridging the gap CME Tbilisi 24/10/2015 Evi Nagler

Programme Hepatitis C HCV-related kidney disease

Programme – not covering Hepatitis C Chronic kidney disease

Programme – not covering Hepatitis C Chronic kidney disease

Programme – not covering Hepatitis C Chronic kidney disease

Hepatitis C virus envelope Single stranded RNA nucleocapsid

Heterogeneous At least 6 different genotypes many many subtypes and strains Differential response to treatment Hinders development of vaccines Gravitz. Nature 2011; 474: S1-S4

Transmission Transfusions IV drug use Re-use

Natural course – acute hepatitis c

Natural course – chronic hepatitis c – 3% population

Natural course – liver cirrhosis

Natural course – liver failure or cancer

Programme Hepatitis C HCV-related kidney disease

3 diseases affect kidney 1. Mixed cryoglobulinaemia syndrome 2. Polyarteritis nodosa 3. Membranous nephropathy

1. Mixed cryoglobulinaemia syndrome Immune complex small-vessel vasculitis

1. Mixed cryoglobulinaemia syndrome Pathophysiology

1. Mixed cryoglobulinaemia syndrome Symptoms Pupura Weakness Arthralgia

1. Mixed cryoglobulinaemia syndrome Normal glomerulus Membranoproliferative GN Thin capillary walls 1-2 cells per capillary tuft Thick capillary walls with Hypercellularity

3 diseases affect kidney 1. Mixed cryoglobulinaemia syndrome 2. Polyarteritis nodosa 3. Membranous nephropathy

Medium-vessel vasculitis 2. Polyarteritis nodosa Medium-vessel vasculitis

2. Polyarteritis nodosa ? Pathophysiology

Fibrinoid necrosis of vessel wall 2. Polyarteritis nodosa Pathophysiology Fibrinoid necrosis of vessel wall White blood cells

2. Polyarteritis nodosa Symptoms Pupura/ulcers Livedo Weakness Arthralgia Fever Abdominal pain

3 diseases affect kidney 1. Mixed cryoglobulinaemia syndrome 2. Polyarteritis nodosa 3. Membranous nephropathy

3. Membranous nephropathy Pathophysiology

3. Membranous nephropathy Normal glomerulus Membranous nephropathy Thin capillary walls Thick capillary walls

3. Membranous nephropathy Symptoms oedema

3 diseases affect kidney 1. Mixed cryoglobulinaemia syndrome 2. Polyarteritis nodosa 3. Membranous nephropathy

2 treatment strategies 1. Antiviral strategies 2. Immunosuppresive strategies

1. Antiviral strategies 1. Peg-Interferon + ribavirin 2. Peg-Interferon + ribavirin + direct-acting antivirals 3. Direct-acting antivirals +/- ribavirin

1. Antiviral strategies - mechanisms 1. Interferon

1. Antiviral strategies - mechanisms 1. Peg-Interferon Poly-ethyleen glycol Interferon

1. Antiviral strategies - mechanism 2. Ribavirin

1. Antiviral strategies - mechanism 2. Direct-acting antivirals

1. Antiviral strategies – viral clearance

1. Antiviral strategies – Side effects Interferon

1. Antiviral strategies – Hypothesis Chronic Hepatitis C Liver failure Death Viral clearance Liver failure Death Chronic Hepatitis C Liver failure Death Viral clearance

1. Antiviral strategies – effectiveness in MCS 1. Peg-Interferon + Ribavirin N=9 No virus=7 Clinical response=7 Stop treatment 1 year 2.5 year Coucoub et al. Arthr&Reum 2005; 52: 911-915

1. Antiviral strategies – effectiveness in MCS ? 2. Peg-Interferon + Ribavirin + direct antivirals

1. Antiviral strategies – safety in CKD 1. Peg-Interferon + Ribavirin Hemolytic Anaemia renal clearance= reduce dose

1. Antiviral strategies – safety in CKD ? 2. Direct antivirals

2 treatment strategies 1. Antiviral strategies 2. Immunosuppressive strategies

2. Immunosuppressive strategies 1. Rituximab 2. Corticosteroids 3. Plasmapheresis 4. Cyclophosphamide

2. Immunosuppressive strategies - MCS 1. Rituximab 2. Corticosteroids 3. Plasmapheresis 4. Cyclophosphamide

2. Immunosuppressive strategies - MCS 1. Rituximab rituximab

2. Immunosuppressive strategies - MCS 1. Rituximab 59 Rituximab Best available alternative De Vita et al. Arthr&Rheum 2012; 64: 843-853

2. Immunosuppressive strategies - MCS 1. Rituximab 2. Corticosteroids 3. Plasmapheresis 4. Cyclophosphamide

2. Immunosuppressive strategies - MCS 2. Corticosteroids Probability of complete response 65 Infα No treatment Infα + 16 mg methylpred 16 mg methylpred Damacco et al. Blood 1994; 64: 843-853

2. Immunosuppressive strategies - MCS 1. Rituximab 2. Corticosteroids 3. Plasmapheresis 4. Cyclophosphamide

Conclusions 3 diseases 2 treatment strategies antiviral immunosuppressive Very few data, mainly in mixed cryoglobulinaemia syndrome

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.